What should I know about Genmab?
Genmab is a Danish biotechnology company based in Copenhagen that develops antibody medicines for cancer and other serious diseases. It is best known for discovering the antibody behind Darzalex, a multiple myeloma drug sold by Johnson & Johnson, from which Genmab earns royalties. It has since added its own medicines, including Epkinly and Tivdak, and has acquired Merus, a cancer antibody company. In the first half of 2026 it reported revenue growth of 25% year on year.
What are Genmab's main drugs?
Darzalex, sold by Johnson & Johnson, is Genmab's biggest source of income through royalties. It contributed about half of first-half revenue growth, rising 21%. Genmab's own medicines include Epkinly, a lymphoma treatment developed with AbbVie, with net sales of DKK 312 million, up 48% on a year earlier, and Tivdak, for cervical cancer, which made DKK 84 million in the first half. Genmab's broader product portfolio grew 35% from a year earlier. It raised its 2026 revenue forecast to DKK 4.3 billion to DKK 4.5 billion.
What is Genmab currently developing?
Genmab has several readouts expected in the fourth quarter of 2026: Phase 2 and 3 data for Rina-S in ovarian cancer, a first-line head and neck cancer study of petosemtamab, and an interim analysis of the Epkinly EPCORE DLBCL-2 trial. It has also started two Phase 3 trials of petosemtamab in a type of colorectal cancer. Genmab raised its forecast for 2026 operating expenses by 2%, reflecting extra investment in development programmes, including the new petosemtamab trials. Its forecast for 2026 operating profit is DKK 1.1 billion to DKK 1.4 billion.
Is Genmab publicly traded, and how big is it?
Yes. Genmab is listed on Nasdaq Copenhagen and its American depositary shares trade on the Nasdaq under the ticker GMAB. MarketScreener put its market value at about $22.2 billion (about DKK 148 billion) in 2026, with the shares at about $37. It is profitable, with operating profit forecast at DKK 1.1 billion to DKK 1.4 billion for 2026, and it expects revenue of DKK 4.3 billion to DKK 4.5 billion.